Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Authors/Creators

• Vincent Doré
• James D. Doecke
• Ziad S. Saad
• Gallen Triana-Baltzer
• Randy Slemmon
• Natasha Krishnadas
• Pierrick Bourgeat
• Kun Huang
• Samantha Burnham
• Christopher Fowler
• Stephanie R. Rainey-Smith, Edith Cowan UniversityFollow
• Ashley I. Bush
• Larry Ward
• Jo Robertson
• Ralph N. Martins, Edith Cowan UniversityFollow
• Colin L. Masters
• Victor L. Villemagne
• Jurgen Fripp
• Hartmuth C. Kolb
• Christopher C. Rowe

Abstract

Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to 18F-NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F-MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2-fold in Aβ+ CU and 3.5-fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVRMT P =.63 (CI, P =.69; CU, P =.34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ− CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ− PET was 0.89, and for tau+ versus tau− PET was 0.89. Discussion: Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET.

Keywords

Alzheimer's disease, amyloid imaging, amyloid plaque, Aβ imaging, blood biomarkers, blood diagnostic for Alzheimer's disease, paired helical filaments, phosphorylated tau, plasma P-tau217, positron emission tomography, tau imaging

Document Type

Journal Article

Date of Publication

1-1-2022

Volume

14

Issue

1

Publication Title

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Publisher

Wiley

School

School of Medical and Health Sciences

RAS ID

54178

Funders

National Health and Medical Research Council Enigma Australia

Grant Number

NHMRC Number: APP1132604, APP1140853, APP1152623

Grant Link

https://researchdata.edu.au/big-nhmrc-adnet-app1152623-rowe/1607739/?refer_q=rows=15/sort=score%20desc/class=activity/p=1/q=APP1152623/

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Comments

Doré, V., Doecke, J. D., Saad, Z. S., Triana-Baltzer, G., Slemmon, R., Krishnadas, N., . . . Rowe, C. C. (2022). Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 14(1), article e12307. https://doi.org/10.1002/dad2.12307